Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clgc.2014.04.004PMID 24861951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic Impact of Baseline Serum C-Reactive Protein in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib

  2014cited by this paper
• Prognostic impact of baseline serum C‐reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib

  2014cited by this paper
• [Sarcomatoid renal cell carcinoma].

  2013cited by this paper
• A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance.

  2013cited by this paper
• Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.

  2013influential reference
• SARCOMATOID RENAL CELL CARCINOMA : CLINICOPATHOLOGIC FINDINGS IN

  2012cited by this paper
• Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

  2012cited by this paper
• Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

  2011cited by this paper
• Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease

  2011influential reference
• Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

  2011cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy

  2010cited by this paper
• Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

  2010cited by this paper
• Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

  2009cited by this paper
• Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• Resistance to targeted therapy in renal-cell carcinoma.

  2009cited by this paper
• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

  2009cited by this paper
• Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

  2009cited by this paper
• Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy

  2009influential reference
• Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

  2008cited by this paper
• Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

  2008cited by this paper
• Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.

  2007influential reference
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Novel approaches in the therapy of metastatic renal cell carcinoma

  2005cited by this paper
• A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma.

  2005cited by this paper
• Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

  2004influential reference
• Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations With Patient Outcome

  2004cited by this paper
• Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.

  2004cited by this paper
• Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.

  2002cited by this paper
• Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

  2002cited by this paper
• Sarcomatoid Differentiation in Renal Cell Carcinoma: A Study of 101 Cases

  2001cited by this paper
• Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies.

  1999cited by this paper
• Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.

  1999cited by this paper
• Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases

  1987cited by this paper
• Sarcomatoid carcinoma of the kidney.

  1987cited by this paper
• Sarcomatoid renal cell carcinoma. A treatable entity

  1987cited by this paper

• Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

  2025cites this paper
• Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)

  2024cites this paper
• A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma

  2024cites this paper
• Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab

  2024cites this paper
• Role of metastasectomy in the management of renal cell carcinoma

  2022cites this paper
• Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium

  2022cites this paper
• Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.

  2022cites this paper
• Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells

  2022cites this paper
• Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review.

  2021cites this paper
• Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data

  2021cites this paper
• MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells

  2020cites this paper
• First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology

  2020cites this paper
• Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

  2020cites this paper
• Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

  2020cites this paper
• Rare Case of Sarcomatoid Renal Cell Carcinoma Metastasis to the Duodenum: Report of a Case and Review of the Literature

  2020cites this paper
• Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.

  2020cites this paper
• Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.

  2020cites this paper
• Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

  2020cites this paper
• Renal-cell carcinoma – novel concepts of classification

  2019cites this paper
• Periokuläre Metastase als Differenzialdiagnose eines „pyogenen Granuloms“ und Therapiemarker einer Systemerkrankung

  2019cites this paper
• Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

  2019cites this paper
• Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas

  2019cites this paper
• A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

  2019cites this paper
• Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?

  2019cites this paper
• Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear‐Cell Renal‐Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors

  2018cites this paper
• Sarcomatoid component and the risk of renal cell carcinoma : a systematic review and meta-analysis

  2018cites this paper
• Pazopanib in the treatment of advanced renal cell carcinoma

  2018cites this paper
• Renal Cell Carcinoma with Sarcomatoid Features

  2018cites this paper
• [Renal cell carcinoma with sarcomatoid and rhabdoid features: a clinico-pathological series of 74 cases].

  2018influential citation
• Пазопаниб в терапии распространенного почечноклеточного рака

  2018cites this paper
• Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient

  2017cites this paper
• Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal‐Cell Carcinoma

  2017cites this paper
• Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm

  2017cites this paper
• Programmed cell death ligand 1 and tumor‐infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation

  2017cites this paper
• Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20‐Year Single‐Institution Experience

  2017cites this paper
• Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma

  2017cites this paper
• Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinib

  2016cites this paper
• Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor

  2016cites this paper
• RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

  2015cites this paper
• Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma.

  2015cites this paper
• Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma

  2015cites this paper
• Carcinosarcomas: tumors in transition?

  2015cites this paper
• Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.

  2015cites this paper
• Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival

  2015cites this paper